Wedbush Equities Analysts Lower Earnings Estimates for MLTX

Key Points

• Wedbush has reduced its Q3 earnings estimates for MoonLake Immunotherapeutics, projecting a loss of ($0.88) per share, compared to a previous estimate of ($0.74).
• The consensus estimate for MoonLake's full-year earnings stands at a loss of ($1.79) per share, indicating a challenging financial outlook for the company.
• Despite the negative earnings outlook, Wedbush maintains an "Outperform" rating with a target price of $80.00 for the stock.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Wedbush cut their Q3 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a report issued on Tuesday, August 5th. Wedbush analyst Y. Zhong now expects that the company will post earnings per share of ($0.88) for the quarter, down from their prior estimate of ($0.74). Wedbush has a "Outperform" rating and a $80.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.29) EPS, FY2026 earnings at ($3.29) EPS, FY2027 earnings at ($3.02) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $3.79 EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period in the previous year, the business earned ($0.39) earnings per share.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Royal Bank Of Canada restated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a "neutral" rating and a $65.00 price target on the stock. Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Finally, The Goldman Sachs Group upped their price objective on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $74.43.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock traded up $0.12 during trading hours on Thursday, reaching $52.52. 104,369 shares of the company's stock were exchanged, compared to its average volume of 481,265. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $58.26. The company has a market cap of $3.36 billion, a P/E ratio of -18.90 and a beta of 1.27. The company's 50 day moving average is $48.87 and its two-hundred day moving average is $43.11. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. LPL Financial LLC boosted its stake in shares of MoonLake Immunotherapeutics by 19.5% in the 4th quarter. LPL Financial LLC now owns 8,146 shares of the company's stock valued at $441,000 after purchasing an additional 1,332 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of MoonLake Immunotherapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock worth $3,192,000 after purchasing an additional 540 shares in the last quarter. FMR LLC increased its stake in shares of MoonLake Immunotherapeutics by 28.1% in the fourth quarter. FMR LLC now owns 6,341,391 shares of the company's stock worth $343,386,000 after purchasing an additional 1,391,167 shares in the last quarter. Mariner LLC bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $272,000. Finally, PEAK6 LLC bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $271,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.